ISPOR Releases Top 10 HEOR Trends Report for 2022-2023

By HEOR Staff Writer

January 17, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a renowned professional society in Health Economics and Outcomes Research (HEOR). Biennially, it publishes a report, outlining the ISPOR Top 10 HEOR Trends. This article explores the 2022-2023 top trends, heavily influenced by the COVID-19 pandemic, and their implications for the healthcare industry.

Real-world Evidence (RWE) – The Number One Trend

RWE has been identified as the top trend for 2022-2023. Its significance has grown due to its crucial role in addressing the pandemic. Health data, which is integral to RWE, also joins the trends list at number nine.

Health Equity – A New Entrant in the Top Trends

The pandemic has starkly highlighted health disparities and their devastating impact. As a result, health equity has emerged as a top trend, ranking third on the list.

Public Health and Health Technology Assessment (HTA) – Rising Trends

Public health has also been elevated in the trends list, ranking seventh, no doubt due to the pandemic’s impact. HTA enters the list at number eight, underlining the importance of evaluating healthcare interventions.

Artificial Intelligence – A Key Player in the Top Trends

Artificial Intelligence (AI) has made its mark, joining the top trends at number ten. It’s clear that healthcare data and AI are becoming increasingly intertwined, driving innovation and efficiency in the sector.


These top trends in HEOR provide valuable insights for all healthcare stakeholders, from researchers and academicians to life sciences industry professionals and patients. They highlight the importance of informed health decisions backed by rigorous, proven methodologies.

 

Reference url

Recent Posts

NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024. The PEPFAR TB impact extends far beyond HIV, delivering substa...
Advancing Collaborative TB Innovation to Tackle Drug Resistance

By João L. Carapinha

March 24, 2026

Collaborative TB Innovation is essential to ending the world’s deadliest infectious disease. Tuberculosis (TB) still claims millions of lives each year, with rising drug resistance, climate-driven migration, and conflict severely undermining global progress. While the burden falls heaviest on low...